The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1−/− myopathic mice
Open Access
- 13 July 2009
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 157 (6), 1045-1052
- https://doi.org/10.1111/j.1476-5381.2009.00316.x
Abstract
Background and purpose: We have investigated the therapeutic effects of the selective cyclophilin inhibitor D‐MeAla3‐EtVal4‐cyclosporin (Debio 025) in myopathic Col6a1−/− mice, a model of muscular dystrophies due to defects of collagen VI. Experimental approach: We studied calcineurin activity based on NFAT translocation; T cell activation based on expression of CD69 and CD25; propensity to open the permeability transition pore in mitochondria and skeletal muscle fibres based on the ability to retain Ca2+ and on membrane potential, respectively; muscle ultrastructure by electronmicroscopy; and apoptotic rates by terminal deoxynucleotidyl transferase‐mediated dUTP nick end labelling assays in Col6a1−/− mice before after treatment with Debio 025. Key results: Debio 025 did not inhibit calcineurin activity, yet it desensitizes the mitochondrial permeability transition pore in vivo. Treatment with Debio 025 prevented the mitochondrial dysfunction and normalized the apoptotic rates and ultrastructural lesions of myopathic Col6a1−/− mice. Conclusions and implications: Desensitization of the mitochondrial permeability transition pore can be achieved by selective inhibition of matrix cyclophilin D without inhibition of calcineurin, resulting in an effective therapy of Col6a1−/− myopathic mice. These findings provide an important proof of principle that collagen VI muscular dystrophies can be treated with Debio 025. They represent an essential step towards an effective therapy for Ullrich Congenital Muscular Dystrophy and Bethlem Myopathy, because Debio 025 does not expose patients to the potentially harmful effects of immunosuppression.This publication has 48 references indexed in Scilit:
- The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patientsHepatology, 2009
- Dephosphorylation by calcineurin regulates translocation of Drp1 to mitochondriaProceedings of the National Academy of Sciences of the United States of America, 2008
- Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophyBritish Journal of Pharmacology, 2008
- Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding AgentAntimicrobial Agents and Chemotherapy, 2008
- Cyclosporin A corrects mitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathiesProceedings of the National Academy of Sciences of the United States of America, 2008
- Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophyNature Medicine, 2008
- The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virusHepatology, 2008
- Preferential chemotaxis of activated human CD4+ T cells by extracellular cyclophilin AJournal of Leukocyte Biology, 2007
- The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesisApoptosis, 2007
- Mitochondrial dysfunction in the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporinsProceedings of the National Academy of Sciences of the United States of America, 2007